• Treatment of acromegaly in patients already adequately controlled on standard doses of Octreotide S.C. Patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. • Endocrine gastro-entero- pancreatic (GEP) tumors, carcinoid tumors.